UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION
                     WASHINGTON, D.C. 20549


                           FORM 8-K/A



                         CURRENT REPORT
             PURSUANT TO SECTION 13 OR 15(D) OF THE
                 SECURITIES EXCHANGE ACT OF 1934

 Date of Report (Date of earliest event reported): November 5, 2003


                   Global Life Sciences, Inc.
               -----------------------------------
     (Exact Name of Registrant as Specified in Its Charter)

                            Nevada
                    ---------------------
         (State or other jurisdiction of incorporation)


         000-33333                       33-9374101
       -------------                 ------------------
  (Commission File Number)    (I.R.S. Employer Identification No.)


   2020 Main Street, Suite 600, Irvine, California     92614
  ------------------------------------------------   --------
     (Address of Principal Executive Offices)       (Zip Code)


                         949-223-7103
                      -------------------
      (Registrant's Telephone Number, including area code)


  (Former Name or Former Address, if Changed Since Last Report)








                          - 2 -




Item 7.   Financial Statements and Exhibits

a.   Financial Statements of Business Acquired


                                    Neudorfstr 18
                                    65239 Hochheim am Main

                                    Grauer Hof 11
                                    38828 Wegeleben OT Adersleben

Dipl. Bw. Frank Kisch

                                                  20. Januar 2004
Independent Auditors' Report

The Stockholders, Members and Board of Directors

We  have  audited  the  combined  balance  sheets  of  Laboratory
Division  of Global Life Sciences, Inc. as of December  31,  2003
and  the  related combined statements of operations,  changes  in
stockholder'  equity and cash flows for the  years  December  31,
2001, 2002 and 2003.  These combined financial statements are the
responsibility  of the Company's management.  Our  responsibility
is  to  express an opinion on these combined financial statements
based on our audits.

We  conducted  our  audits in accordance with auditing  standards
generally  accepted  in  the United  States  of  America.   Those
standards  require that we plan and perform the audit  to  obtain
reasonable   assurance  about  whether  the  combined   financial
statements are free of material misstatement.  An audit  included
examining,  on a test basis, evidence supporting the amounts  and
disclosures in the combined financial statements.  An audit  also
includes assessing the accounting principles used and significant
estimates  made by management, as well as evaluating the  overall
combined  financial statement presentation.  We believe that  our
audits  of the combined financial statements provide a reasonable
basis for our opinion.

In  our  opinion, the combined balance sheets referred  to  above
present  fairly, in all material respects, the financial position
of  Laboratory Division of Global Life Sciences, Inc. as  of  the
years  December 31, 2001, 2002 and 2003 and the results of  their
operations and their cash flows for the years December 31,  2001,
2002 and 2003, in conformity with accounting principles generally
accepted in the United States of America.

Mit freundlichen GruBen

/s/ Frank Kisch
- -------------------
Diplom Betriebswirt





                          - 3 -










                                    Combined Financial Statements

                Laboratory Division of Global Life Sciences, Inc.

                                                December 31, 2003
                                                December 31, 2002
                                                December 31, 2001
























                          - 4 - F1





        Laboratory Division of Global Life Sciences, Inc.

                  Combined Financial Statements

                        December 31, 2003
                        December 31, 2002
                        December 31, 2001

           (With Independent Auditors' Report Thereon)
























                          - 5 - F2






        Laboratory Division of Global Life Sciences, Inc.

                        Table of Contents




Combined Balance Sheets                                          F4
Combined Statements of Operations                                F5
Combined Statements of Changes in Stockholders' Equity           F6
Notes to Combined Financial Statements                           F7






                      (all figures in Euro)


















                          - 6 - F3





        Laboratory Division of Global Life Sciences, Inc.

                    Combined Balanced Sheets

                        December 31, 2003
                        December 31, 2002
                        December 31, 2001



                             Assets

- --------------------------------------------------------------------------------------
 Current assets:                             December 31,  December 31,  December 31,
                                                 2003          2002          2001
- --------------------------------------------------------------------------------------
                                                                     

 Cash (including restricted cash of EUR)      153.123,58     98.269,32    129.345,28
 Accounts receivable                           85.258,32     73.214,73     65.502,22
 Prepaid expenses and other current assets     41.583,10     31.254,26     23.001,60
 Total current assets                         279.965,00    202.738,31    217.849,10
 Property and equipment, net (note 2)       2.998.000,00  2.785.000,00  2.575.000,00
 Other assets (intangible)                  3.257.000,00  2.975.000,00  2.745.000,00
 Total combined assets                      6.534.965,00  5.962.738,31  5.537.849,10
- --------------------------------------------------------------------------------------






                Liabilities Stockholders' Equity

- --------------------------------------------------------------------------------------
 Current liabilities:                        December 31,  December 31,  December 31,
                                                 2003          2002          2001
- --------------------------------------------------------------------------------------
                                                                     

 Accounts payable                              85.633,12     78.256,47     63.599,23
 Accounts expenses                             21.458,59     15.385,38     11.486,81
 Due to stockholders (note 3)                  20.000,00            --            --
 Stockholders' Equity                       6.407.873,29  5.869.096,46  5.462.763,06
 Total current liabilities                  6.534.965,00  5.962.738,31  5.537.849,10
- --------------------------------------------------------------------------------------






See notes to combined financial statements.




                          - 7 - F4





        Laboratory Division of Global Life Sciences, Inc.

                Combined Statements of Operations





- --------------------------------------------------------------------------------------
 Revenue:                                    December 31,  December 31,  December 31,
                                                 2003          2002          2001
- --------------------------------------------------------------------------------------
                                                                     

 Customer group 1:                            813.934,50    792.760,48    750.905,35

 "Nahrungsmittelallergie, Insekten-und           855           837           811
 Medikamentenunvertragrichkeit"               customers     customers     customers
- --------------------------------------------------------------------------------------
 Customer group 2:                            895.834,22    830.560,99    795.890,40

 "Umwelterkrankungen,                            962           941           905
 Nahrungsmittelzusatze"                       customers     customers     customers
- --------------------------------------------------------------------------------------
 Customer group 3:                            410.921,82    385.750,65    401.304,32

 "Immunologische-und Hormonunter-                434           417           423
 suchungen bei Anti Aging Patienten"          customers     customers     customers
- --------------------------------------------------------------------------------------
 Other                                         15.900,00      5.300,50     22.305,25
- --------------------------------------------------------------------------------------
 Net revenues                               2.136.590,54  2.014.372,62  1.970.405,32
- --------------------------------------------------------------------------------------







- --------------------------------------------------------------------------------------
 Costs and expenses:                         December 31,  December 31,  December 31,
                                                 2003          2002          2001
- --------------------------------------------------------------------------------------
                                                                     

 Cost of revenues                           1.798.931,05  1.722.387,38  1.650.540,59
 Selling, general and administrative          167.877,20    152.303,55    120.560,12
 Total expenses                             1.966.808,25  1.874.690,93  1.771.100,71
 Net income (loss)                            169.782,29    139.681,69    199.304,61
- --------------------------------------------------------------------------------------






See note to combined financial statements.






                          - 8 - F5




        Laboratory Division of Global Life Sciences, Inc.

     Combined Statements of Changes in Stockholders' Equity



                        December 31, 2003
                        December 31, 2002
                        December 31, 2001


The lab's shareholders (Prof. Dr. Dr. Hans-Jurgen Reimann and Dr.
Antje Reimann) have chosen to operate the lab as sole
proprietorship; hence there were no shares issued nor outstanding
in the reporting period.  In Q4, 2003, the shareholders decided
to sell the lab to Global Life Sciences,  Inc. and therefore
entered into an asset purchase agreement in order to sell all
assets to the public company (we did not analyze or audit the
stockholders' equity of Global Life Sciences, Inc.).









See notes to combines financial statements.









                          - 9 - F6




        Laboratory Division of Global Life Sciences, Inc.

             Notes to Combined Financial Statements


                        December 31, 2003
                        December 31, 2002
                        December 31, 2001



1.)  Organization and summary of Significant Accounting Policies

     a.)  Corporate Organization

          ---

     b.)  Income Taxes

          The  combined financial statements include the accounts
          of the lab, which have elected to be taxed under German
          law.

     c.)  Property and Equipment

          see appraisal

     d.)  Revenue Recognition

          The  lab recognizes revenue generally upon payment  for
          services rendered.

     e.)  Advertising Costs

          Advertising  expenditures related to service  promotion
          and marketing efforts are expenses as incurred.

     f.)  Use of Estimates

          Management  of  the lab has made certain estimates  and
          assumptions  relating to the reporting  of  assets  and
          liabilities and the disclosure of contingent assets and
          liabilities   to   prepare  these  combined   financial
          statements   in  conformity  with  generally   accepted
          accounting  principles.  Actual  results  could  differ
          from those estimates.

     g.)  Financial Instruments Fair Value, Concentration of Business
          and Credit Risks

          ---

     h.)  Cash Flow

          Fore  purposes  of  cash flows, the lab  considers  all
          highly  liquid investments with an initial maturity  of
          three months or less to be cash equivalents.




                          - 10 - F7




2.)  Property and Equipment

     Property  and equipment, net, consist of the following:  see
     appraisal.

     ---

3.)  Due to Stockholders

     Advances from certain stockholders have been made to the lab
     primarily  for  working capital purposes.   Amounts  due  to
     stockholders  represent non-interest bearing advances  which
     are due on demand.

4.)  Operating Lease Commitments

     ---

5.)  Common Stock

     No common stock as been issued nor authorized as the lab has
     been operated as sole proprietorship (see above.)

6.)  Disclaimer

     The  audit is based on financial data provided by management
     and  Prof. Dr. Dr. Reimann.  As the lab was operated as sole
     proprietorship we had only access to data required by German
     law  for such sole proprietorships.  I conducted my analysis
     and   review  in  accordance  with  auditing  and  appraisal
     standards  generally  accepted  in  the  United  States   of
     America.   I  believe  that my appraisals  of  the  combined
     assets provide a reasonable basis for my opinion and that  I
     the  analysis has been performed to the best of my knowledge
     and belief as independent auditor.












                          - 11 - F8





                           SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

                         GLOBAL LIFE SCIENCES, INC.


February 25, 2004             By: /S/ PROF. DR. DR. HANS-JURGEN REIMANN
                                  -------------------------------------
                              PROF. DR. DR. HANS-JURGEN REIMANN
                              President and Chief Executive Officer





























                          - 12 -